Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook 2018: Industry Analysis with Future Forecast till 2025

This report studies the global 23-Valent Pneumococcal Polysaccharide Vaccine market status and forecast, categorizes the global 23-Valent Pneumococcal Polysaccharide Vaccine market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.

23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.

Request Sample Copy of Report @ https://www.qyresearch.com/sample-form/form/164497/global-23-valent-pneumococcal-polysaccharide-vaccine-sales-market

North America is the largest supplier and consumption market of 23-Valent Pneumococcal Polysaccharide Vaccine, with a production market share nearly 70% and sales market share nearly 28% in 2015. Because Sanofipasteur, a competitor from Europe, transferred its vaccine type gradually, the production market share of North America in the world has enjoyed a dramatic increase.

The second place is EU, following North America with production market share of 15% and sales market share nearly 20% in 2015.China is another important market of 23-Valent Pneumococcal Polysaccharide Vaccine, enjoying 10% production market share and 15% sales market share in 2015.

The global 23-Valent Pneumococcal Polysaccharide Vaccine market is valued at 1550 million US$ in 2017 and will reach 4550 million US$ by the end of 2025, growing at a CAGR of 14.4% during 2018-2025.

The major players covered in this report

MSD

Sanofipasteur

CDIBP

…

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

United States

Europe

China

Japan

Southeast Asia

India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Single Dose Vial

Pre-filled Syringe

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

For Children (2-10)

For Person (10-64)

For The Old (≥65)

Benefits of Purchasing QY Research Report
• Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report
• Customer’s Satisfaction: Our expert team will assist with all your research needs and customize the report
• Inimitable Expertise: Analysts will provide deep insights about the reports
• Assured Quality: We focus on the quality and accuracy of the report

Buy Full Report Now, Report delivery time within 24 hours @ https://www.qyresearch.com/settlement/pre/a122e227c866b0ce557a37de86865530,0,1,Global%2023-Valent%20Pneumococcal%20Polysaccharide%20Vaccine%20Sales%20Market%20Report%202018

About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Contact US:
QY Research, INC.
17890 Castleton,
Suite 218,
Los Angeles, CA – 91748
USA: +1 626 295 2442
Email: enquiry@qyresearch.com
Web: http://www.qyresearch.com

This release was published on openPR.